| GENERAL INFORMATION | |||
|---|---|---|---|
| Company name: | Modiblast Pharma GmbH | ||
| Address: | Buchenstr. 3, 82041 Oberhaching, Germany | ||
| Web: | https://www.modiblast.com | ||
| Company creation date: | 2020 | ||
| Employees: | 4 | ||
| Field of activity: | Human | ||
| Record last updated on: | 02/03/2023 | ||
| CONTACT DETAILS | |||
| Contact name: | Helga Schmetzer | ||
| Tel: | +49 89 1226 4666 | ||
| Fax: | |||
| Email: | contact@modiblast.com | ||
| COMPANY SECTOR | |||
| (Bio)Pharmaceutical: | |||
| Early manufacturing/Research&Discovery stage: | |||
| Development stage: | |||
| Commercialisation/Marketing stage (EU/Non-EU): | |||
| Medical Device and Technology: | |||
| Development stage: | |||
| Commercialisation/Marketing stage (EU/Non-EU): | |||
| PRODUCT INFORMATION | |||
| Medicinal Products | |||
| Vaccines: | |||
| Therapeutic medicines: | |||
| Diagnostic and imaging products: | |||
| Combined medicinal products and devices: | |||
| Product Development Stages | Number of Products |
||
| Research/Discovery: | 1 |
||
| Pharmaceutical development: | 0 |
||
| Preclinical: | 1 |
||
| Clinical exploratory: | 0 |
||
| Clinical confirmatory: | |||
| (Pre)registration (EU/Non-EU): | |||
| Marketing (EU/Non-EU): | |||
| SUBSTANCES | |||
| Chemicals | |||
| Single entities | |||
| Combinations of single entities | |||
| Peptides (chemically synthesised) | |||
| Biologically derived proteins and peptides | |||
| Monoclonal antibodies | |||
| Recombinant proteins | |||
| Extracted proteins | |||
| Nucleic acids (chemically synthesised) | |||
| RNA | |||
| DNA | |||
| Polymer (natural and synthetic - excluding peptides, proteins and nucleic acids) | |||
| Homopolymers | |||
| Copolymers | |||
| Advanced therapy medicinal products (in accordance with EC 1394/2007) | |||
| Somatic cell therapy products | |||
| Tissue engineered products | |||
| Gene therapy products | |||
| Radionuclides | |||
| Allergens | |||
| Polyclonal immunoglobulins | |||
| Herbal derived complex substances | |||
| Animal derived complex substances | |||
| SPECIFIC PRODUCT CATEGORIES | |||
| Biodefense | |||
| Biosimilars | |||
| Excipients | |||
| Foods (Functional foods, nutraceuticals) | |||
| Generics | |||
| Genetically modified organisms (GMOs) | |||
| Homeopathics | |||
| Maximum Residue Limits (Veterinary products) | |||
| Medical devices | |||
| Medicines for tropical diseases | |||
| MUMS (Minor Use/Minor Species) /Limited Market (Veterinary products) | |||
| Nanotechnology (including microparticles, liposomes, microbeads) | |||
| New formulations/delivery methods | |||
| Orphan medicines (in accordance with Orphan Drug Regulation EC/141/2000) | |||
| OTC (Over the counter)/Non prescription/self medication | |||
| Paediatric medicines | |||
| Stem cells | |||
| Theranostics (personalised/targeted products, biomarkers,(pharmaco)genomics) | |||
| Transgenic technology | THERAPEUTIC AREA (assigned or expected ATC codes) | ||
| A Alimentary tract and metabolism | |||
| B Blood and blood forming organs | |||
| C Cardiovascular system | |||
| D Dermatologicals | |||
| G Genito-urinary system and sex hormones | |||
| H Systemic hormonal preparations, excluding sex hormones | |||
| J General anti-infectives for systemic use | |||
| L Anti-neoplastic and immunomodulating agents | |||
| M Musculo-skeletal system | |||
| N Nervous system | |||
| P Anti-parasitic products, Insecticides, Repellents | |||
| R Respiratory system | |||
| S Sensory organs | |||
| V Various | |||
| Back to list | |||